Can You Lose Belly Fat with Mounjaro? Exploring the Effectiveness of Tirzepatide

Last reviewed: June 6, 2026

Last updated: June 6, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Belly fat, or visceral adipose tissue, is metabolically active and linked to insulin resistance and cardiovascular risk. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has demonstrated significant reductions in abdominal fat deposits in clinical trials. PlexusDx provides access to compounded tirzepatide through licensed 503A pharmacies, available nationwide without insurance.

How Tirzepatide Targets Belly Fat Loss

Tirzepatide works by stimulating two hormone receptors simultaneously: GLP-1 receptors and GIP receptors. These dual pathways slow stomach emptying, increase feelings of fullness after smaller meals, and enhance insulin secretion when blood sugar rises. Together, they create a sustained reduction in calorie intake and improve metabolic efficiency.

Visceral fat—the deep abdominal fat surrounding organs—responds particularly well to GIP and GLP-1 activation because these receptor sites are concentrated in fat tissue and the brain regions controlling hunger. Studies show that tirzepatide reduces visceral adiposity more effectively than single-pathway medications, addressing not just weight loss but metabolic health.

Clinical Evidence for Tirzepatide Effectiveness

The SURMOUNT trials, which evaluated tirzepatide across multiple dose levels, reported average weight reductions of 20–22% over 68 weeks in participants with obesity. Importantly, imaging studies within these trials documented substantial reductions in visceral and subcutaneous belly fat, not just overall body weight. Participants also showed improvements in markers like HbA1c, blood pressure, and cholesterol.

A secondary analysis of SURMOUNT data revealed that tirzepatide reduced waist circumference by 4–5 inches on average, with the largest reductions seen in individuals carrying the most abdominal fat at baseline. This targeted effect on belly fat—rather than proportional loss across all body regions—makes tirzepatide unique among weight loss medications.

Tirzepatide vs. Other Belly Fat Loss Options

Single GLP-1 agonists like semaglutide work primarily through appetite suppression and delayed gastric emptying. Tirzepatide's additional GIP pathway adds a second mechanism: enhanced insulin sensitivity and altered fat cell metabolism. This dual action produces greater visceral fat loss than GLP-1 alone, though individual results depend on genetics and lifestyle.

Diet and exercise remain foundational, but they often plateau when fighting metabolic resistance. Tirzepatide addresses the hormonal drivers of belly fat accumulation, making it an effective complement to behavioral changes. PlexusDx offers both compounded semaglutide ($189/mo) and tirzepatide ($289/mo) so patients and providers can choose the approach best matched to their genetic and metabolic profile.

Personalizing Tirzepatide Therapy with Genetic Testing

Not everyone responds identically to tirzepatide because genetic variations affect how strongly GLP-1 and GIP receptors function. PlexusDx Precision Peptide Genetic Test ($298) analyzes key variants including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These variants influence appetite regulation, fat storage, and metabolic rate.

Patients with certain genetic profiles may show faster belly fat loss, require lower doses, or benefit from combining tirzepatide with semaglutide through PlexusDx's GLP-Squared formulations. After the first month of treatment, adding the genetic test allows PlexusDx providers to map 14 peptide pathways and refine therapy. This personalization helps maximize fat loss while minimizing side effects and cost.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much belly fat can I lose with tirzepatide in three months?

Individual results vary, but clinical trials show average waist circumference reductions of 1–1.5 inches per month during the first three months. Faster results often appear in those with higher baseline visceral fat. PlexusDx providers monitor progress and adjust dosing to optimize belly fat loss while keeping your monthly cost flat at $289/mo for the injection.

Is tirzepatide better than semaglutide for losing belly fat specifically?

Yes, tirzepatide's dual GLP-1 and GIP action produces greater visceral fat reduction than single-pathway GLP-1 therapy. However, semaglutide remains highly effective and costs less ($189/mo vs. $249/mo). PlexusDx Precision Peptide Genetic Testing can help describe the pathway-level variants involved.

What is PlexusDx's tirzepatide pricing and how do I start?

Compounded tirzepatide injection is $289/mo month-to-month, or from $249/mo on the 6-month plan across all commitment tiers—your dose may increase, but your price remains $289/mo flat. PlexusDx serves all 50 states without insurance or membership fees and accepts HSA/FSA funds. You can complete a consultation online and have medication shipped to your home from a licensed 503A compounding pharmacy.

Are there side effects with tirzepatide for belly fat loss?

Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These typically diminish within 1–2 weeks as your body adapts. Serious adverse events are rare but include pancreatitis and thyroid concerns; inform your provider of personal or family history. PlexusDx providers monitor safety closely and can slow titration if needed.

How does the Precision Peptide Genetic Test help with tirzepatide response?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (FTO) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Tirzepatide Mounjaro
• Tirzepatide Vs Mounjaro
• Mounjaro Vs Tirzepatide
• Mounjaro Tirzepatide

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.